Literature DB >> 1321253

Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion.

Y Ohe1, Y Sasaki, T Shinkai, K Eguchi, T Tamura, A Kojima, H Kunikane, H Okamoto, A Karato, H Ohmatsu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1321253     DOI： 10.1093/jnci/84.12.972

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  28 in total

Review 1.  Breast cancer therapies in development. A review of their pharmacology and clinical potential.

Authors:  D de Valeriola; A Awada; J A Roy; A Di Leo; L Biganzoli; M Piccart
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of irinotecan.

Authors:  G G Chabot
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

3.  Irinotecan plus cisplatin combination against metastatic gastric cancer: phase II study.

Authors:  Mustafa Altinbas; Ozlem Er; Metin Ozkan; Yusuf Solak; H Senol Coskun; Can Kucuk; Sebnem Gursoy
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 4.  Adaptive control methods for the dose individualisation of anticancer agents.

Authors:  A Rousseau; P Marquet; J Debord; C Sabot; G Lachâtre
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

Review 5.  Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.

Authors:  L R Wiseman; A Markham
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 6.  Emerging drug treatments for solid tumours.

Authors:  J H Schellens; L C Pronk; J Verweij
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

7.  Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38.

Authors:  G G Chabot
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 8.  Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.

Authors:  Umang Swami; Sanjay Goel; Sridhar Mani
Journal:  Curr Drug Targets       Date:  2013-06       Impact factor: 3.465

Review 9.  Camptothecins: a review of their chemotherapeutic potential.

Authors:  Hulya Ulukan; Peter W Swaan
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan.

Authors:  L P Rivory; J Robert
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.